Giaccone G
Department of Oncology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands.
Semin Oncol. 1999 Feb;26(1 Suppl 4):19-24.
Among the relatively new cytotoxic agents that are active in non-small cell lung cancer, gemcitabine and the taxanes (paclitaxel and docetaxel) are certainly of particular interest due to their essentially nonoverlapping toxicities and single-agent activities, which compare favorably with single-agent cisplatin. For these reasons, new combinations including these agents are being tested in dose-finding studies in phase II and III trials. Combinations of gemcitabine with a taxane, with or without a platinum compound, represent new and promising regimens for the treatment of non-small cell lung cancer and other tumor types.
在对非小细胞肺癌有效的相对较新的细胞毒性药物中，吉西他滨和紫杉烷类（紫杉醇和多西他赛）因其基本不重叠的毒性和单药活性而备受关注，与单药顺铂相比具有优势。基于这些原因，包含这些药物的新联合方案正在II期和III期试验的剂量探索研究中进行测试。吉西他滨与紫杉烷类联合，无论是否添加铂类化合物，都代表了治疗非小细胞肺癌和其他肿瘤类型的新的、有前景的方案。
